PDF]US Food and Drug Administration Grants Breakthrough Therapy Designation for Mogamulizumab for the treatment of Mycosis Fungoides and Sézary Syndrome Kyowa Hakko Kirin News Releases
[PDF]美国食品和药物管理局授予Mogamulizumab用于治疗真菌病真菌和Sézary综合征的突破性治疗指定 协和Hakko麒麟新闻稿
http://www.kyowa-kirin.com/news_releases/2017/pdf/e20170825_01.pdf